- Supported exchanges /
- F /
- 7V7.F
ACTICOR BIOTECH EO 1 (7V7 F) stock market data APIs
Acticor Biotech SAS operates as a clinical stage biopharmaceutical company that develops drugs for the treatment for acute thrombotic diseases. The company develops glenzocimab, a humanized monoclonal antibody fragment that targets platelet glycoprotein VI. It's product glenzocimab is in Phase 2/3 clinical trial, as well as completed Phase 1b/2a for the treatment of acute ischemic stroke; and Phase 2/3 clinical trial for treatment of cerebrovascular accidents in emergency situations, as well as completed Phase 2 clinical trial for treating acute respiratory distress syndrome (covid-19). The company has collaboration agreement with the University of Birmingham for Phase 2b clinical trials of glenzocimab in treating heart attacks. The company was incorporated in 2013 and is headquartered in Paris, France.
ACTICOR BIOTECH EO 1 Financial Data Overview
0.746 | |
0.746 | |
- | |
0.746 | |
0.746 | |
0.222-4.07 | |
11 571 K | |
15 510 K | |
0 | |
0.124 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
ACTICOR BIOTECH EO 1 Fundamental Data is available in our Financial Data APIs
- Net Revenue 0
- EBITDA -16 837 000
- Earnings Per Share -1.54
- Income Statements
- Balance Sheets
- Cash flows
of Fundamental API Data
Get ACTICOR BIOTECH EO 1 Earnings via APIs
- Latest Release NaN
- EPS/Forecast NaN
Get ACTICOR BIOTECH EO 1 End-of-day Data via APIs
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: